An announcement from Madrigal Pharmaceuticals ( (MDGL) ) is now available.
On March 9, 2025, Fred Craves announced his resignation from Madrigal Pharmaceuticals’ Board of Directors, effective July 1, 2025, without any disagreements with the company. Subsequently, the Board expanded to include Jackie Fouse, Ph.D., an experienced biotech executive, who will serve on the Audit and Nominating and Governance Committees. This change reflects Madrigal’s commitment to leadership in the MASH sector, with plans to drive the launch of Rezdiffra, expand geographically, and advance their clinical program.
More about Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with significant unmet medical needs. Their primary product, Rezdiffra (resmetirom), is the first FDA-approved medication for treating MASH with moderate to advanced fibrosis.
YTD Price Performance: 4.90%
Average Trading Volume: 412,812
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: $7.27B
Learn more about MDGL stock on TipRanks’ Stock Analysis page.